Evidence map›Paper›PMID 41356786›Full record

ArticlePulmonary circulation2025

Improvement in Right Ventricular Function and Pulmonary Pressures in Patients With Severe Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction Treated With Sacubitril-Valsartan.

Bahy Abofrekha, Jennifer Jdaidani, Mahmoud Shadi, Elie Bou Sanayeh, Alaukika Agarwal, Nadim Zaidan, Geurys R Rojas-Marte

Abstract read
In one paragraph

Article in Pulmonary circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bahy AbofrekhaDepartment of Internal Medicine, Northwell Staten Island University Hospital New Hyde Park New York USA.ORCID https://orcid.org/0009-0007-8086-2928
Jennifer JdaidaniDepartment of Internal Medicine, Northwell Staten Island University Hospital New Hyde Park New York USA.
Mahmoud ShadiCardiovascular Institute, Northwell Staten Island University Hospital New Hyde Park New York USA.
Elie Bou SanayehDepartment of Internal Medicine, Northwell Staten Island University Hospital New Hyde Park New York USA.
Alaukika AgarwalDepartment of Internal Medicine, Northwell Staten Island University Hospital New Hyde Park New York USA.
Nadim ZaidanDepartment of Internal Medicine, Northwell Staten Island University Hospital New Hyde Park New York USA.ORCID https://orcid.org/0000-0003-0988-9494
Geurys R Rojas-MarteDepartment of Cardiology Deborah Heart and Lung Center Browns Mills New York USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary hypertension (PH) significantly impacts outcomes in heart failure with preserved ejection fraction (HFpEF), especially with right ventricular dysfunction (RVD), yet effective treatments are limited. This study retrospectively evaluated sacubitril-valsartan's effects on pulmonary pressures, RV function, and clinical outcomes in 20 severe HFpEF-PH patients. Significant improvements were observed over a median 397-day follow-up. Sacubitril-valsartan notably reduced RV systolic pressure (RVSP) by 27.50 mmHg (

Indexed as

heart failure with preserved ejection fractionHFpEF‐PHpulmonary hypertensionright ventricular functionRV‐PA couplingSacubitril‐valsartan

Identifiers

PMID41356786
PMCPMC12675304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.